An observational study in Dengue Fever, sponsored by University of Heidelberg Medical Center. Completed at 9 sites in 8 countries. Open to participants aged 5 Years and older. Per ClinicalTrials.gov, last updated 2016-10-11.
Sponsored by University of Heidelberg Medical Center · Observational
Improvements in diagnosis of dengue fever and prediction of which patients will get more severe disease are urgently needed to improve the treatment of patients with dengue. This is very important in places with many people who suffer from dengue but have limited health care resources. This study will enroll patients with fever which may be caused by dengue in 6 countries with high incidence of dengue over two continents (Brazil, Cambodia, El Salvador, Indonesia, Malaysia and Vietnam). All patients will be followed by a doctor with blood tests and exams until they recover. Symptoms and laboratory tests will be followed so that the cause of fever can be determined. For patients who have dengue, the investigators will look for symptoms and tests which indicate more serious disease. This study will help to determine how to identify patients with dengue fever based on symptoms and simple laboratory tests and those who will get more serious disease. It will also help to define a more standardized management of patients with dengue fever.
Improvements in clinical diagnosis of dengue and risk prediction for severe disease are urgently needed to improve overall clinical care, especially in settings with a high case burden where appropriate allocation of limited resources is crucial to outcome. In this work package 10,000 outpatients with undifferentiated fever, consistent with possible dengue, will be recruited within 3 days of fever onset in 6 endemic countries (Brazil, Cambodia, El Salvador, Indonesia, Malaysia and Vietnam), and will be followed daily until full recovery. Clinical features and simple laboratory parameters differentiating dengue from other febrile illness will be identified, and, among those with confirmed dengue, risk factors for progression to more severe disease will be evaluated. As well as contributing to the development of diagnostic and prognostic algorithms the clinical cohort has considerable potential towards standardisation of procedures for dengue management and reporting.
279 studies on the registry are indexed under Dengue; 45 are open to participants now.
This study's enrollment of 7,411 is above the median of 595 across 78 observational studies indexed under Dengue.
Browse Dengue studies →University of Heidelberg Medical Center is the lead sponsor of 21 studies on the registry; 3 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Febrile patients presenting to outpatient clinic
Exclusion Criteria:
Observation of patients with possible dengue fever in the early phase of disease
Other: Observation
Clinical follow-up and laboratory investigations.
Hospitalization or administration of IV fluid
Proportion of dengue patients hospitalized or treated with IV fluids within 14 days of enrollment.
Time frame: 14 days
Development of severe disease
Development of severe disease according to the 2009 WHO Dengue classification within 14 days of enrollment.
Time frame: 14 days
Plan to share: No
This study is completed, as verified in Oct 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Heidelberg Medical Center